Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
TSS
MCID: TXC005
MIFTS: 66

Toxic Shock Syndrome (TSS)

Categories: Infectious diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Toxic Shock Syndrome

About this section

MalaCards integrated aliases for Toxic Shock Syndrome:

Name: Toxic Shock Syndrome 12 77 56 15 74
Septic Shock 17 3
Staphylococcal Toxic Shock Syndrome 74
Shock, Septic 45
Toxic Shock 12
Tss 12

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:14115
ICD9CM 36 040.82
MeSH 45 D012772
NCIt 51 C35498
SNOMED-CT 69 18504008
ICD10 34 A48.3 R57.2
Sources

Summaries for Toxic Shock Syndrome

About this section
Disease Ontology : 12 A commensal bacterial infectious disease that results in infection, has material basis in Streptococcus pyogenes or has material basis in Staphylococcus aureus , which produce toxins that are absorbed systemically and produce the systemic manifestations. The infection has symptom fever, has symptom rash, has symptom hypotension, has symptom multiorgan failure, has symptom desquamation, has symptom vomiting, has symptom diarrhea, has symptom headache, and has symptom nonfocal neurologic abnormalities.

MalaCards based summary : Toxic Shock Syndrome, also known as septic shock, is related to staphylococcal toxic shock syndrome and streptococcal toxic-shock syndrome, and has symptoms including hypotension, fever and vomiting. An important gene associated with Toxic Shock Syndrome is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Dexmedetomidine and Propofol have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and skin, and related phenotypes are hematopoietic system and homeostasis/metabolism

CDC : 3 Educational Materials

Wikipedia : 77 Toxic shock syndrome (TSS) is a condition caused by bacterial toxins. Symptoms may include fever, rash,... more...

Sources

Related Diseases for Toxic Shock Syndrome

About this section

Diseases related to Toxic Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 653)
# Related Disease Score Top Affiliating Genes
1 staphylococcal toxic shock syndrome 34.2 CIITA HMGB1 IFNG IL1B TNF
2 streptococcal toxic-shock syndrome 33.4 C1S CXCL8 IL2 IL6 LTA MYOM2
3 fasciitis 31.2 CXCL8 IL6 TNF
4 burns 31.0 IL1B SERPINC1 TNF
5 acute respiratory distress syndrome 30.9 CXCL8 IL1B IL6 LTA TNF
6 kawasaki disease 30.8 IL10 IL6 TNF
7 pharyngitis 30.7 CXCL8 IL1B MYOM2
8 necrotizing fasciitis 30.6 CXCL8 IL2 IL6 LTA MYOM2
9 chikungunya 30.6 IL1B IL6 TNF
10 acute pyelonephritis 30.6 CXCL8 IL10 IL6
11 joint disorders 30.5 IL1B IL6 TNF
12 shigellosis 30.4 CXCL8 IL10 LTA
13 adult respiratory distress syndrome 30.4 CXCL8 IL10 IL6 TNF
14 vaginitis 30.4 CXCL8 IL1B IL6
15 leukomalacia 30.4 IL6 TNF
16 purpura 30.3 IL6 SERPINC1 TNF
17 reactive arthritis 30.3 IFNG IL10 TNF
18 cytomegalovirus infection 30.3 CXCL8 IL1B IL6 TNF
19 mastitis 30.3 CXCL8 IL6 TLR2
20 spotted fever 30.3 IFNG IL10 TNF
21 endomyocardial fibrosis 30.3 IL10 IL4 TNF
22 endometritis 30.3 IL1B IL6 TNF
23 bacterial pneumonia 30.2 CXCL8 IL6 TLR4
24 dengue shock syndrome 30.2 IL1B IL6 TNF
25 sudden infant death syndrome 30.2 IL10 IL1B IL6 TNF
26 arteries, anomalies of 30.2 IL1B IL6 SERPINC1 TNF
27 temporal arteritis 30.2 IFNG IL6 TNF
28 scleritis 30.1 IFNG IL4 TNF
29 acute pancreatitis 30.1 CXCL8 IL10 IL6
30 hepatitis a 30.1 IFNG IL10 TNF
31 cystitis 30.1 CXCL8 IL6 TLR4 TNF
32 herpes zoster 30.1 IFNG IL10 IL2
33 chronic graft versus host disease 30.1 IFNG IL10 TNF
34 severe acute respiratory syndrome 30.0 CXCL8 IFNG TNF
35 pyelonephritis 30.0 CXCL8 IL10 IL1B IL6 TLR4 TNF
36 churg-strauss syndrome 30.0 HMGB1 IL10 TNF
37 pulmonary fibrosis, idiopathic 30.0 CXCL8 IFNG IL1B TNF
38 bacterial sepsis 29.9 CXCL8 IL10 TLR4 TNF
39 hemophagocytic lymphohistiocytosis 29.9 CXCL8 IFNG IL10 TNF
40 noonan syndrome 1 29.8 CXCL8 IL1B IL2 IL6 TNF
41 rheumatic fever-related antigen 29.8 MYOM2 TLR2
42 prostatitis 29.8 CXCL8 IL10 IL1B IL2 IL6 TNF
43 pericarditis 29.8 IFNG IL1B IL6 TNF
44 monoclonal gammopathy of uncertain significance 29.8 IL6 LTA MYOM2 TNF
45 infective endocarditis 29.7 IL6 TLR2 TNF
46 myeloma, multiple 29.7 CXCL8 IL2 IL6 MYOM2 TNF
47 pleurisy 29.7 CXCL8 IFNG IL2 TNF
48 pulmonary disease, chronic obstructive 29.7 CXCL8 IL6 TLR2 TNF
49 acquired immunodeficiency syndrome 29.7 IFNG IL10 IL1B IL2 IL6 TNF
50 osteomyelitis 29.7 CXCL8 IFNG IL10 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Toxic Shock Syndrome:



Diseases related to Toxic Shock Syndrome
Sources

Symptoms & Phenotypes for Toxic Shock Syndrome

About this section

Symptoms:

12
  • • hypotension
  • • fever
  • • vomiting
  • • diarrhea
  • • headache
  • • desquamation
  • • rash
  • • multiorgan failure
  • • nonfocal neurologic abnormalities

UMLS symptoms related to Toxic Shock Syndrome:


shock without mention of trauma

MGI Mouse Phenotypes related to Toxic Shock Syndrome:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.32 CIITA IFNG IL10 IL1B IL2 IL4
2 homeostasis/metabolism MP:0005376 10.3 CIITA IFNG IL10 IL1B IL2 IL4
3 immune system MP:0005387 10.28 CIITA IFNG IL10 IL1B IL2 IL4
4 cardiovascular system MP:0005385 10.22 IFNG IL10 IL1B IL2 IL6 LTA
5 endocrine/exocrine gland MP:0005379 10.15 CIITA IFNG IL10 IL2 IL4 IL6
6 digestive/alimentary MP:0005381 10.11 IFNG IL10 IL2 IL4 IL6 TLR2
7 liver/biliary system MP:0005370 10.07 IFNG IL10 IL2 IL4 IL6 LTA
8 neoplasm MP:0002006 10.02 IFNG IL10 IL1B IL2 IL6 MIF
9 integument MP:0010771 10.01 IFNG IL10 IL1B IL4 IL6 TLR2
10 nervous system MP:0003631 10 IFNG IL10 IL1B IL4 IL6 LTA
11 respiratory system MP:0005388 9.81 IFNG IL10 IL2 IL4 IL6 LTA
12 skeleton MP:0005390 9.65 CIITA IFNG IL10 IL1B IL4 IL6
13 vision/eye MP:0005391 9.28 IFNG IL10 IL2 IL4 IL6 LTA
Sources

Drugs & Therapeutics for Toxic Shock Syndrome

About this section

Drugs for Toxic Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 476)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
2
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
3
Simvastatin Approved Phase 4,Phase 2,Phase 3 79902-63-9 54454
4
Milrinone Approved Phase 4 78415-72-2 4197
5
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
6
Ceftriaxone Approved Phase 4,Phase 3,Not Applicable 73384-59-5 5479530 5361919
7
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
10
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
11
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 5496 36294
12
Nefopam Approved, Investigational Phase 4 13669-70-0
13
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3 27203-92-5 33741
14
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
15
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Clonidine Approved Phase 4,Phase 2,Phase 3 4205-90-7 2803
18
Meropenem Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 119478-56-7, 96036-03-2 441130 64778
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 22916-47-8 4189
20
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-03-3
21
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-23-7 5754
22
Protein C Approved Phase 4,Phase 3,Phase 2
23
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
24
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
25
Tazobactam Approved Phase 4,Phase 2,Phase 3,Not Applicable 89786-04-9 123630
26
Piperacillin Approved Phase 4,Phase 2,Phase 3,Not Applicable 66258-76-2 43672
27
Dobutamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 34368-04-2 36811
28
Methylene blue Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 61-73-4
29
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 329-65-7 838
30
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 51-43-4 5816
31
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 32051
32
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 14636-12-5 72081
33
Imipenem Approved Phase 4,Phase 2,Phase 3,Not Applicable 74431-23-5, 64221-86-9 104838
34
Cilastatin Approved, Investigational Phase 4,Phase 2,Phase 3 82009-34-5 6435415 5280454
35
Vancomycin Approved Phase 4,Phase 2,Phase 3,Not Applicable 1404-90-6 441141 14969
36
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
37
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 2826718 468682
38
Ephedrine Approved Phase 4,Phase 2 299-42-3 9294
39
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
40
Oxymetazoline Approved, Investigational Phase 4,Phase 2 1491-59-4 4636
41
Pseudoephedrine Approved Phase 4,Phase 2 90-82-4 7028
42
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
43
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
44
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
45
carbamide peroxide Approved Phase 4,Not Applicable 124-43-6
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
47
Polymyxin B Approved, Vet_approved Phase 4,Phase 3,Not Applicable 1404-26-8
48
Adenosine Approved, Investigational Phase 4,Phase 1 58-61-7 60961
49
Dipyridamole Approved Phase 4 58-32-2 3108
50
Nitroglycerin Approved, Investigational Phase 4,Phase 3 55-63-0 4510

Interventional clinical trials:

(show top 50) (show all 832)
# Name Status NCT ID Phase Drugs
1 Early Goal Directed Sedation on Microcirculation in Septic Shock Unknown status NCT02612363 Phase 4 Dexmedetomidine for sedation
2 Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China Unknown status NCT02647554 Phase 4 ulinastatin;Placebo
3 Simvastatin in Patients With Septic Shock Unknown status NCT00450840 Phase 4 Simvastatin
4 Early Continuous Renal Replacement Therapies (CRRT) in Patients With Severe Sepsis or Septic Shock With Acute Kidney Injury Unknown status NCT00837057 Phase 4
5 Effects of Levosimendan, Milrinone and Norepinephrine on Left and Right Ventricular Function in Septic Shock Unknown status NCT02640846 Phase 4 Norepinephrine;Milrinone;Levosimendan
6 COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2 Unknown status NCT01639664 Phase 4
7 Pharmacokinetic of Ceftriaxone in Septic ICU Patients Unknown status NCT00449800 Phase 4 ceftriaxone
8 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
9 Influence of Moderate Inspired Oxygen Fraction (FiO2) and Protective Ventilation on Postoperative Pulmonary Complication Unknown status NCT02198625 Phase 4
10 Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia Unknown status NCT02440828 Phase 4 tobramycin inhalation;placebo
11 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
12 Transpulmonary Thermodilution and Transesophageal Echocardiography in Early Septic Shock Completed NCT01188993 Phase 4
13 Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units Completed NCT02213796 Phase 4 Meropenem
14 Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis Completed NCT02805049 Phase 4 Echinocandins
15 Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock. Completed NCT02768740 Phase 4 Hydrocortisone hemisuccinate
16 Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension Completed NCT02519699 Phase 4 norepinephrine
17 Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C Completed NCT02885168 Phase 4 Recombinant Activated Protein C;Phenylephrine
18 Dexmedetomidine on Microcirculation in Septic Shock Completed NCT02270281 Phase 4 Dexmedetomidine 0.7 Mcg/kg/h
19 ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock Completed NCT01448109 Phase 4 Hydrocortisone;Sterile air filled vial
20 Early Albumin Resuscitation During Septic Shock Completed NCT00327704 Phase 4 albumin;saline
21 Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Completed NCT02079402 Phase 4 Isotonic crystalloids
22 Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock Completed NCT00279214 Phase 4 drotrecogin alfa (activated)
23 Effect of Different Strategies for Titrating a High MAP on Microcirculation Completed NCT02085291 Phase 4 Norepinephrine;Crystalloid
24 Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock Completed NCT02730624 Phase 4 Piperacillin-tazobactam
25 Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock Completed NCT02266264 Phase 4 Hydrocortisone
26 Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock Completed NCT01310790 Phase 4
27 Norepinephrine Weaning in Septic Patients Completed NCT00763906 Phase 4
28 Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue Completed NCT03120637 Phase 4 Methylene Blue
29 BaSES Trial: Basel Starch Evaluation in Sepsis Completed NCT00273728 Phase 4 hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
30 Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department Completed NCT02365272 Phase 4 Amikacin
31 The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment of Sepsis Completed NCT00329680 Phase 4
32 Adrenal Cortical Function and Vitamin A Deficiency in Sepsis Completed NCT03152474 Phase 4 Solumedrol 20mg;Vitamin A 100,000 IU
33 Influence of Age, Sepsis and SLCO1A2 Polymorphisms on Rocuronium Pharmacokinetics Completed NCT02399397 Phase 4 General anesthesia
34 Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis Completed NCT00629382 Phase 4
35 Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
36 Intraoperative Protective Ventilation in Abdominal Surgery (IMPROVE Study) Completed NCT01282996 Phase 4
37 Evaluating the Influence of Ready-to-use (RTU) Parenteral Nutrition in the Clinical Outcome of Patients Study Completed NCT00798681 Phase 4
38 Low-dose Hydrocortisone in Acutely Burned Patients Completed NCT00149123 Phase 4 hydrocortisone 200 mg/day
39 Effects of Vasopressors on Immune Response Completed NCT02675868 Phase 4 Norepinephrine;Phenylephrine;Vasopressins;Placebo
40 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia Completed NCT01091571 Phase 4 Dipyridamole;Placebo
41 The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation Completed NCT01099566 Phase 4 Prasugrel;Placebo
42 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
43 Probiotics in the Prevention of Complications After Colorectal Surgery Completed NCT02313519 Phase 4
44 Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment Completed NCT01559753 Phase 4 Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin;compare 8 to15 days of antibiotic treatment
45 Ketamine Versus Etomidate for Rapid Sequence Intubation Completed NCT01823328 Phase 4 Ketamine;Etomidate
46 Intravenous Clarithromycin in Septic Syndrome Completed NCT00297674 Phase 4 Intravenous Clarithromycin
47 Propafenone Versus Amiodarone in Septic Shock Recruiting NCT03029169 Phase 4 Propafenone i.v.;Amiodarone i.v.
48 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial Recruiting NCT03668236 Phase 4 Isotonic crystalloids
49 Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study Recruiting NCT03336814 Phase 4 Terlipressin
50 Ketamine Versus Fentanyl for Induction of Anesthesia in Septic Shock Recruiting NCT03251170 Phase 4 Ketamine;Fentanyl;Midazolam

Search NIH Clinical Center for Toxic Shock Syndrome

Cochrane evidence based reviews: shock, septic

Sources

Genetic Tests for Toxic Shock Syndrome

About this section
Sources

Anatomical Context for Toxic Shock Syndrome

About this section

MalaCards organs/tissues related to Toxic Shock Syndrome:

42
Kidney, T Cells, Skin, Lung, Neutrophil, Brain, Testes
Sources

Publications for Toxic Shock Syndrome

About this section

Articles related to Toxic Shock Syndrome:

(show top 50) (show all 1617)
# Title Authors Year
1
Myocardial calcification secondary to toxic shock syndrome: a comparative review of 17 cases. ( 30635313 )
2019
2
Streptococcal toxic shock syndrome caused by β-hemolytic streptococci: Clinical features and cytokine and chemokine analyses of 15 cases. ( 30744988 )
2019
3
Contribution of toxic shock syndrome toxin-1 to systemic inflammation investigated by a mouse model of cervicovaginal infection with Staphylococcus aureus. ( 29980843 )
2018
4
The effect of vaginal microbial communities on colonization by Staphylococcus aureus with the gene for toxic shock syndrome toxin 1 (TSST-1): a case-control study. ( 29762733 )
2018
5
Clinical and Molecular Epidemiology of Staphylococcal Toxic Shock Syndrome in the United Kingdom. ( 29350159 )
2018
6
Draft Genome Sequence of Streptococcus suis Strain SsRC-1, a Human Isolate from a Fatal Case of Toxic Shock Syndrome. ( 29773639 )
2018
7
Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. ( 29788397 )
2018
8
The Evaluation and Management of Toxic Shock Syndrome in the Emergency Department: A Review of the Literature. ( 29366615 )
2018
9
Periocular Necrotizing Fasciitis with Toxic Shock Syndrome. ( 29928226 )
2018
10
RS3PE syndrome developing during the course of probable toxic shock syndrome: a case report. ( 29653519 )
2018
11
Epidemiology and Clinical Relevance of Toxic Shock Syndrome in US Children. ( 29601458 )
2018
12
Molecular characterization and antibiotic resistance of Streptococcus dysgalactiae subspecies equisimilis isolated from patients with streptococcal toxic shock syndrome. ( 29107650 )
2018
13
Frequency of enterotoxins, toxic shock syndrome toxin-1, and biofilm formation genes in Staphylococcus aureus isolates from cows with mastitis in the Northeast of Brazil. ( 29429115 )
2018
14
Fulminant streptococcal toxic shock syndrome. ( 29741523 )
2018
15
Innate immune responses following Kawasaki disease and toxic shock syndrome. ( 29447181 )
2018
16
Successful Treatment of Streptococcal Toxic Shock Syndrome with Both Diffuse Peritonitis and Necrotizing Fasciitis. ( 30510834 )
2018
17
Fasciitis and Streptococcal Toxic-shock Syndrome: The Importance of Early Diagnosis and Surgical Management. ( 30740378 )
2018
18
Uncommon cause of pelvic inflammatory disease leading to toxic shock syndrome. ( 30249728 )
2018
19
Streptococcal toxic shock syndrome with primary group A streptococcus peritonitis in a healthy female. ( 30356961 )
2018
20
Impact of Currently Marketed Tampons and Menstrual Cups on Staphylococcus aureus Growth and Toxic Shock Syndrome Toxin 1 Production In Vitro. ( 29678918 )
2018
21
Epidemiology of toxic shock syndrome toxin-1 harboring Staphylococcus aureus obtained from clinical samples in Iran: A Systematic Review and Meta-analysis. ( 30062367 )
2018
22
Survival from Clostridium toxic shock syndrome: Case report and review of the literature. ( 30081323 )
2018
23
Clinical Manifestations and Bacterial Genomic Analysis of Group A Streptococcus Strains That Cause Pediatric Toxic Shock Syndrome. ( 30085250 )
2018
24
Streptococcal toxic shock syndrome - a life-threatening condition caused by various streptococcal species. ( 30126285 )
2018
25
Successful treatment of out-of-hospital cardiopulmonary arrest due to streptococcal toxic shock syndrome - effectiveness of extracorporeal membrane oxygenation and the rapid antigen group A streptococcus test: a case report. ( 30170621 )
2018
26
The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential. ( 30175438 )
2018
27
Streptococcal toxic shock syndrome in the intensive care unit. ( 30225523 )
2018
28
Carriage of the Toxic Shock Syndrome Toxin Gene by Contemporary Community-Associated Staphylococcus aureus Isolates. ( 30285124 )
2018
29
Postpartum Methicillin-Resistant Staphylococcus aureus Toxic Shock Syndrome Caused by a Perineal Infection. ( 30363971 )
2018
30
Streptococcal toxic shock syndrome in a returning traveller. ( 30369302 )
2018
31
Streptococcus pyogenes bacteremia and toxic shock syndrome related to Strongyloides stercoralis hyperinfection: a case report. ( 30463627 )
2018
32
Toxic shock syndrome: the great masquerader. ( 30567096 )
2018
33
Streptococcal toxic shock syndrome caused by the dissemination of an invasive emm3/ST15 strain of Streptococcus pyogenes. ( 29254479 )
2017
34
Complete Genome Sequence and Comparative Genomics of a Streptococcus pyogenes emm3 Strain M3-b isolated from a Japanese Patient with Streptococcal Toxic Shock Syndrome. ( 28698738 )
2017
35
Intense, flu-like symptoms in women using menstrual devices: always think of staphylococcal Toxic Shock Syndrome. ( 28580155 )
2017
36
Group A Streptococcal Peritonitis and Toxic Shock Syndrome in a Postmenopausal Woman. ( 28824068 )
2017
37
Macro- and Microvascular Parameters Following Toxic Shock Syndrome. ( 29112091 )
2017
38
Toxic shock syndrome, tampons and laboratory standard-setting. ( 28536130 )
2017
39
Rare presentation of necrotising fasciitis and streptococcal toxic shock syndrome by group A streptococcus. ( 28954758 )
2017
40
Post-partum streptococcal toxic shock syndrome associated with necrotizing fasciitis. ( 28725564 )
2017
41
Toxic shock syndrome in paediatric thermal injuries: A case series and systematic literature review. ( 28867411 )
2017
42
Case of toxic shock syndrome triggered by negative-pressure wound therapy. ( 28862320 )
2017
43
Toxic Shock Syndrome: Still a Timely Diagnosis. ( 29040243 )
2017
44
Erratum: Intense, flu-like symptoms in women using menstrual devices: always think of staphylococcal Toxic Shock Syndrome. ( 28721224 )
2017
45
Infective Endocarditis Associated with Streptococcal Toxic Shock Syndrome due to <i>Streptococcus dysgalactiae</i> subsp. <i>equisimilis</i> Infection in a Hemodialysis Patient. ( 29457020 )
2017
46
Vaccine against toxic shock syndrome in a first-in-man clinical trial. ( 27918218 )
2017
47
Toxic shock syndrome due to community-acquired methicillin-resistant Staphylococcus aureus infection: Two case reports and a literature review in Japan. ( 28491813 )
2017
48
HLA-DR polymorphisms influence in vivo responses to staphylococcal toxic shock syndrome toxin-1 in a transgenic mouse model. ( 27863161 )
2017
49
Successful Treatment of Necrotizing Fasciitis and Streptococcal Toxic Shock Syndrome with the Addition of Linezolid. ( 28299216 )
2017
50
Prevalence, comorbidities and mortality of toxic shock syndrome in United States children and adults. ( 28892185 )
2017
Sources

Variations for Toxic Shock Syndrome

About this section

ClinVar genetic disease variations for Toxic Shock Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TNF TNF, -308G-A single nucleotide variant risk factor
Sources

Expression for Toxic Shock Syndrome

About this section
Search GEO for disease gene expression data for Toxic Shock Syndrome.
Sources

Pathways for Toxic Shock Syndrome

About this section

Pathways related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.11 C1S CIITA CXCL8 HMGB1 IFNG IL10
2
PEDF Induced Signaling 65
Show member pathways
 13.79 CXCL8 IFNG IL10 IL1B IL2 IL4
3
TGF-Beta Pathway 65
Show member pathways
 13.63 CXCL8 IFNG IL10 IL1B IL2 IL4
4
Akt Signaling 65
Show member pathways
 13.54 CXCL8 IL10 IL1B IL2 IL4 IL6
5
Cytokine Signaling in Immune system 67
Show member pathways
 13.49 CIITA CXCL8 IFNG IL10 IL1B IL2
6
PAK Pathway 65
Show member pathways
 13.4 CXCL8 IL10 IL1B IL2 IL4 IL6
7
IL-2 Pathway 65
Show member pathways
 13.34 HMGB1 IFNG IL1B IL2 IL4 TLR2
8
Toll-like Receptor Signaling Pathway 38 1
Show member pathways
 13.34 CXCL8 IFNG IL10 IL1B IL2 IL6
9
PI3K-Akt signaling pathway 38
Show member pathways
 13.06 IL2 IL4 IL6 TLR2 TLR4 TNF
10
Allograft rejection 1 38
Show member pathways
 13.04 CIITA CXCL8 IFNG IL10 IL1B IL2
11
Human cytomegalovirus infection 38
Show member pathways
 13.03 CXCL8 IL1B IL6 TLR2 TLR4 TNF
12
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 67
Show member pathways
 12.91 CXCL8 HMGB1 IFNG IL1B IL6 TLR4
13
Pathways in cancer 38
12.89 CXCL8 IFNG IL2 IL4 IL6
14
NF-KappaB Family Pathway 65
Show member pathways
 12.86 IL1B IL2 IL6 LTA TLR2 TLR4
15
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.84 IL2 IL4 IL6 LTA TNF
16
Th17 cell differentiation 38
Show member pathways
 12.77 IFNG IL10 IL1B IL2 IL4 IL6
17
NF-kappaB Signaling 4
12.75 CIITA IFNG IL10 IL1B IL2 IL4
18
Immune response IL-23 signaling pathway 23
Show member pathways
 12.73 IFNG IL10 IL1B IL2 IL6 TNF
19
Immune response NFAT in immune response 23
Show member pathways
 12.71 IFNG IL10 IL2 IL4 TNF
20
TRAF Pathway 65
Show member pathways
 12.69 IL1B LTA TLR2 TLR4 TNF
21
Influenza A 38
Show member pathways
 12.63 CIITA CXCL8 IFNG IL1B IL2 IL4
22
T cell receptor signaling pathway 38
Show member pathways
 12.62 IFNG IL10 IL1B IL2 IL4 IL6
23
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.55 IFNG IL2 IL4 TNF
24
IL-17 Family Signaling Pathways 66
Show member pathways
 12.52 CXCL8 IFNG IL1B IL4 IL6 TLR2
25
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.51 IFNG IL10 IL2 IL4 IL6
26
Selenium Micronutrient Network 1
Show member pathways
 12.5 IFNG IL1B IL2 IL4 IL6 TNF
27
Toll Comparative Pathway 65
Show member pathways
 12.5 CXCL8 IFNG IL1B IL6 MIF TLR4
28
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.43 CXCL8 IFNG